Kidney transplant recipients (KTRs) face a unique and profound vulnerability to cancer. Chronic immunosuppression—essential for graft survival—greatly increases the risk of malignancy compared with the general population. In fact, the overall cancer risk after kidney transplantation is estimated to be two to four times higher than that of age-matched nontransplant controls.1,2 At the same time, minority and socioeconomically disadvantaged populations often have lower rates of cancer screening, reduced access to high-quality care, and worse survival after a diagnosis of cancer.3,4 For these patients, the convergence of biologic risk5 and systemic inequities posits a unique threat to post-transplantation outcomes. The field has made substantial progress in understanding cancer after transplantation, enabled in part by the remarkable Transplant Cancer Match (TCM) Study.6 By linking national transplant and cancer registry data, the TCM resource has generated unprecedented insights into post-transplant malignancy, influencing approaches to screening, surveillance, and management practices. Despite these advances, the effect of social determinants of health (SDoH) on cancer outcomes after kidney transplantation remains largely unexplored. In this issue of Kidney360, Ng et al. address this gap by leveraging the TCM dataset to examine neighborhood socioeconomic status, measured by the Yost index, in relation to cancer incidence, stage at diagnosis, and cancer-specific survival among adult kidney-only transplant recipients.7 Using a retrospective cohort design, they stratified neighborhood disadvantage by Yost quintiles and assessed overall outcomes as well as for seven cancer types. Key findings were both provocative and clinically meaningful. Recipients from the most disadvantaged neighborhoods had higher lung cancer incidence and were more likely to present with advanced-stage melanoma. Conversely, prostate cancer incidence was lower among disadvantaged recipients—a finding that may reflect disparities in screening utilization. Most importantly, cancer-specific mortality was significantly higher among recipients from disadvantaged neighborhoods, even after adjustment for demographic and clinical factors. Perspective and Commentary This work highlights the value of linking geocoded socioeconomic data with large-scale clinical registries. By applying the Yost index, the authors move beyond documenting cancer incidence to demonstrate how neighborhood context influences stage at diagnosis and cancer-specific survival—outcomes that directly relate to clinical decision-making and patient care. Several strengths warrant recognition. The authors applied rigorous methods across a large, diverse cohort, and extended the conversation about transplant oncology into the realm of social context. In doing so, they expand our understanding of how neighborhood-level disadvantage compounds biologic vulnerability in transplant recipients. Certain limitations merit discussion. The degree of missing geocoded data are not fully reported, raising questions about representativeness. This may be compounded by the study's handling of race. While the authors appropriately controlled for race in multivariable analyses, this approach precluded assessment of how race and neighborhood disadvantage may intersect to shape cancer outcomes. Given the deep entanglement of structural racism, place-based disadvantage, and health care access in the United States, this represents a critical area for future study. Indeed, as Ng et al. acknowledge, neighborhood disadvantage and race/ethnicity are closely intertwined, and one might therefore expect analyses of race to yield findings parallel to those of neighborhood deprivation. Yet the results here diverge from prior TCM-based work. In a 2013 study, Hall et al. reported significantly higher prostate cancer incidence among Black KTRs—who have been historically disadvantaged—compared with White recipients.8 By contrast, Ng and colleagues found lower prostate cancer incidence among recipients from more disadvantaged neighborhoods.7 Whether this discrepancy reflects varied approaches in statistical modeling, temporal shifts, or nuances inherent to sociodemographic variables remains uncertain, but it raises important questions about the relationship between race, neighborhood context, and cancer risk in this population. Broader Implications and Future Directions This study is the first to evaluate the influence of SDoH on cancer outcomes among KTRs, and its implications for practice are direct. Patients from disadvantaged neighborhoods may benefit from targeted strategies after transplant, including enhanced screening, patient navigation, and survivorship programs tailored to socially vulnerable groups. Nevertheless, several important questions remain. How do race and neighborhood disadvantage jointly influence cancer outcomes? Does one magnify the effects of the other? The choice of socioeconomic index also warrants discussion. While the Yost index is widely used and endorsed by the National Cancer Institute Surveillance, Epidemiology, and End Results Program, there are multiple other well-validated measures that assess different SDoH factors and ultimately provide varied insight into the nuances of SDoH and clinical outcomes.9 One notable example is how the Index of Concentration at the Extremes captures racialized economic segregation more directly.10 Applying multiple indices in parallel may offer a fuller understanding of how structural racism and economic deprivation converge to shape cancer risk and outcomes after transplant. Finally, translation into practice remains the ultimate goal. Frameworks should be developed to embed social risk assessment into cancer screening guidelines for transplant patients. Research that links socioeconomic disadvantage to actionable interventions—whether through policy, resource allocation, or programmatic screening strategies—will be critical. Conclusion The study by Ng et al. represents an important advance in understanding how social determinants influence oncologic outcomes after kidney transplantation. By demonstrating that neighborhood disadvantage is associated with cancer-specific variations in incidence, advanced stage at presentation, and survival, the authors highlight both a challenge and an opportunity. For clinicians, the message is clear: Transplant recipients' health is determined not only by immunosuppressive regimens and oncologic therapies, but also by the neighborhoods in which they live and the resources to which they have access. The task ahead is to design interventions that address these disparities head-on, ensuring that the life-saving gift of transplantation yields its full potential for all patients. Continued efforts in this area will be essential to direct resources toward vulnerable populations, safeguard the longevity and quality of life for transplant recipients, and ensure the best use of a scarce and precious resource.
Loszko et al. (Sun,) studied this question.